Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10966358 | Vaccine | 2013 | 7 Pages |
Abstract
In this first trial conducted with HIV-infected immunologically stable adults in South America, both PPV23 and PCV7 were safe and immunogenic. Evidence suggesting PCV7 was more immunogenic than PPV23, as it elicited higher and persistent â¥4-fold increase of antibodies for 6B and 9V serotypes in a greater proportion of HIV-patients is noteworthy. Despite current recommendation of schedules combining PCV7 and PPV23, there is little evidence to support this practice and we did not observe benefits in this combination.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Yeh-Li Ho, Angela Pires Brandão, Maria Cristina de Cunto Brandileone, Marta Heloisa Lopes,